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Abstract 
We review recent evidence concerning the significance of inhibitory GABA transmission and 
of neural disinhibition, i.e. deficient GABA transmission, within prefrontal cortex and 
hippocampus for clinically relevant cognitive functions. Both regions support important 
cognitive functions, including attention and memory, and their dysfunction has been 
implicated in cognitive deficits characterizing neuropsychiatric disorders. GABAergic 
inhibition shapes cortico-hippocampal neural activity and, recently, prefrontal and 
hippocampal neural disinhibition has emerged as a pathophysiological feature of major 
neuropsychiatric disorders, especially schizophrenia and age-related cognitive decline. 
Regional neural disinhibition, disrupting spatio-temporal control of neural activity and 
causing aberrant drive of projections, may disrupt processing within the disinhibited region 
and efferent regions. Recent studies in rats showed that prefrontal and hippocampal neural 
disinhibition (by local GABA antagonist microinfusion) dysregulates burst firing, which has 
been associated with important aspects of neural information processing. Using translational 
tests of clinically-relevant cognitive functions, these studies showed that prefrontal and 
hippocampal neural disinhibition disrupts regional cognitive functions (including prefrontal 
attention and hippocampal memory function); moreover, hippocampal neural disinhibition 
disrupted attentional performance, which does not require the hippocampus, but requires 
prefrontal-striatal circuits modulated by the hippocampus. However, some prefrontal and 
hippocampal functions (including inhibitory response control) are spared by regional 
disinhibition. We consider conceptual implications of these findings, regarding the distinct 
relationships of distinct cognitive functions to prefrontal and hippocampal GABA tone and 
neural activity. Moreover, the findings support that prefrontal and hippocampal neural 
disinhibition contributes to clinically relevant cognitive deficits, and we consider 
pharmacological strategies for ameliorating cognitive deficits by rebalancing disinhibition-
induced aberrant neural activity. 
 
Non-approved abbreviations 
AHP, afterhyperpolarization 
5-CSRT, 5-choice-serial-reaction-time 
DMTP, delayed-matching-to-place 
mGluR, metabotropic glutamate receptor 
PAM, positive allosteric modulator 
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Introduction 
Cognitive deficits, including attentional and memory deficits, are a cross-diagnostic symptom 
of many neuropsychiatric disorders that causes substantial functional disability and is a major 
treatment challenge; a prominent idea is that dysfunction within the prefrontal cortex and 
hippocampus causes such cognitive deficits (Millan et al., 2012). In this review, we will 
begin by highlighting evidence that hippocampal and prefrontal neural disinhibition, i.e. 
deficient inhibitory GABA function, is a key neuropathological feature of important 
neuropsychiatric disorders characterized by cognitive deficits, including schizophrenia and 
age-related cognitive decline (Table 1). Although inhibitory GABA neurotransmission has 
emerged as a key factor in shaping neural activity in neocortex, including prefrontal cortex, 
and hippocampus (Buzsaki and Wang, 2012; Isaacson and Scanziani, 2011; Mann and 
Paulsen, 2007), direct evidence for a causal contribution of prefrontal and hippocampal 
neural disinhibition to clinically relevant cognitive deficits has been lacking until recently. 
We will highlight that neural disinhibition within prefrontal cortex or hippocampus has the 
potential to disrupt cognitive processing mediated by these regions and efferent sites, because 
regional inhibitory GABA transmission may be important to maintain balanced levels of 
neural activity within these respective regions, as well as in their projection sites. The review 
will, then, focus on recent studies examining the neural and cognitive impact of prefrontal 
and hippocampal reductions in inhibitory GABA tone by acute intra-cerebral microinfusions 
of GABA antagonists in rats, using in vivo electrophysiology and translational behavioural 
assays of clinically relevant cognitive functions. These studies revealed that prefrontal and 
hippocampal neural disinhibition causes aberrant neural activity within the disinhibited 
regions and impairs key cognitive functions, including attention and memory, in a way that is 
consistent with regional neural disinhibition disrupting cognitive processing of the 
disinhibited regions and their projection sites. We will consider the theoretical implications of 
these findings, concerning the distinct relationships of regional inhibitory GABA tone and 
neural activity to distinct cognitive functions, their clinical implications, as well as potential 
pharmacological strategies to rebalance disinhibition-induced aberrant neural activity in order 
to ameliorate cognitive impairments. 
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Prefrontal and hippocampal neural disinhibition in neuropsychiatric disorders 
characterized by cognitive deficits 
Prefrontal cortex and hippocampus play key roles in important cognitive functions, including 
attention and everyday memory (Bast, 2007; Bast, 2011; Chudasama and Robbins, 2006). 
Over the past 20 years, neural disinhibition, i.e. reduced inhibitory GABA function, within 
these regions has emerged as a common feature of major neuropsychiatric disorders 
characterized by impairments in these important cognitive functions (Table 1). 
The most compelling evidence comes from studies on the neurobiological mechanisms 
underlying schizophrenia. Alterations in GABA-related post-mortem markers consistent with 
reduced prefrontal and hippocampal inhibitory GABA neuron function are a key 
neuropathological feature of schizophrenia, and many rodent models of schizophrenia show 
similar evidence for such neural disinhibition (Benes and Berretta, 2001; Heckers and 
Konradi, 2015; Lewis and Moghaddam, 2006; Lisman et al., 2008; O'Donnell, 2011; Ruzicka 
et al., 2015). The well-characterized schizophrenia-related cognitive and behavioural changes 
caused by NMDA receptor antagonists in humans and animal models have also been linked 
to neural disinhibition, with reduced GABAergic inhibition in hippocampus and neocortex 
being a key effect of NMDA receptor antagonists, possibly reflecting a blockade of NMDA 
receptor-mediated excitation of inhibitory GABA neurons (Anticevic et al., 2012; Lisman et 
al., 2008; Moghaddam and Krystal, 2012). Given that inhibitory GABA neurons play a key 
role in shaping hippocampal and neocortical neural oscillations (Buzsaki and Wang, 2012; 
Mann and Paulsen, 2007), neural disinhibition may also, at least partly, explain the aberrant 
oscillatory brain activity revealed by EEG and MEG measures in patients with schizophrenia 
(Lisman et al., 2008; Uhlhaas and Singer, 2012). Finally, neural disinhibition may underlie 
regional brain hyperactivity reported by clinical imaging studies of early-stage schizophrenia 
(Anticevic et al., 2015; Heckers and Konradi, 2015; Schobel et al., 2013; Schobel et al., 
2009). More recently, consistent evidence for cortico-hippocampal neural hyperactivity due 
to neural disinhibition has also emerged in cognitive aging and early stages of Alzheimer’s 
disease, with clinical and animal model studies showing a compromised inhibitory GABA 
system and aberrant increases in neural activity (Bakker et al., 2012; Busche and Konnerth, 
2016; Haberman et al., 2017; Huang and Mucke, 2012; Robitsek et al., 2015; Sanchez et al., 
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2012; Schwab et al., 2013; Sperling et al., 2010; Spiegel et al., 2013; Stanley et al., 2012; 
Thomé et al., 2016; Verret et al., 2012; Wilson et al., 2006)
1
.  
In the long term, aberrant neural activity due to GABA dysfunction may lead to 
compensatory adjustments and excitotoxicity that could underlie the regional brain 
hypoactivity and atrophy characterising later stages of schizophrenia and age-related 
cognitive disorders (Anticevic et al., 2015; Heckers and Konradi, 2015; Huang and Mucke, 
2012; Krystal and Anticevic, 2015). Direct evidence for this possibility comes from 
longitudinal functional and structural imaging studies in schizophrenia patients and in a 
rodent model of schizophrenia, in which hippocampal metabolic overactivity in the prodrome 
or at early stages of the mouse model predicted hippocampal atrophy in patients who had 
progressed to schizophrenia or at later stages of the mouse model, respectively (Schobel et 
al., 2013). However, as described in the following, independent of the induction of atrophy, 
aberrant prefrontal and hippocampal neural activity caused by reduced GABA function may 
cause clinically relevant cognitive deficits, and recent studies in rodent models support this. 
 
 
Regional neural disinhibition may disrupt processing within the disinhibited region and 
in efferent sites 
Inhibitory neurotransmission by GABA, which balances and controls excitatory 
neurotransmission, is important for shaping neural activity in hippocampus and neocortex, 
including prefrontal cortex (Buzsaki and Wang, 2012; Isaacson and Scanziani, 2011; Mann 
and Paulsen, 2007). Tightly controlled, spatio-temporally specific neuronal disinhibition, i.e. 
temporary reductions in the GABAergic inhibition of specific synaptic pathways, may open 
windows for enhanced processing of relevant stimuli, thereby facilitating learning and 
memory and, potentially, other cognitive processes (Letzkus et al., 2015). However, tonic 
                                                          
1
 Increased hippocampal neural activity may, at first glance, appear at odds with another hippocampal 
biomarker of cognitive ageing: in vitro electrophysiological recordings from hippocampal slices of aged rabbits 
and rats consistently reveal an enhanced post-burst afterhyperpolarization (AHP) in pyramidal neurons of the 
hippocampal CA1 subregion, which results in hypoexcitability of these neurons (Oh et al., 2010). However, 
contrasting such hypoexcitability in CA1, the CA3 subregion of the aged rat hippocampus shows 
hyperexcitability in vitro (Simkin et al., 2015). These regional differences reported in vitro chime with some in 
vivo studies indicating that CA3 is the main locus of hippocampal neural hyperactivity associated with cognitive 
ageing in humans and rats (Bakker et al., 2012; Wilson et al., 2006). In light of the emerging evidence of 
hippocampal neural hyperactivity in aging, it has been suggested that the hypoexcitability in CA1 neurons may 
be a compensatory response to increased activity at CA3-CA1 synapses due to CA3 hyperexcitability (Simkin et 
al., 2015).     
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neural disinhibition
2
 within a brain region that is not restricted to specific synapses may 
disrupt both regional function and distal function in efferent brain sites (Fig. 1). First, by 
interfering with spatio-temporal control of regional neural activity, neural disinhibition within 
a brain region is likely to disrupt normal regional function. For example, single-neuron 
recording studies in animal models show that stimulus-selective, task-appropriate tuning of 
neurons in the sensory cortices (Isaacson and Scanziani, 2011) and in the prefrontal cortex 
(Rao et al., 2000) requires intact GABA transmission. Second, by causing aberrant drive of 
projections, regional disinhibition may disrupt normal neural activity in efferent sites, thereby 
disrupting the normal function of these efferent sites. These two general hypotheses support 
two specific hypotheses concerning the cognitive impact of prefrontal and hippocampal 
neural disinhibition. First, given the importance of prefrontal cortex for attention (Chudasama 
and Robbins, 2006) and of hippocampus for everyday types of memory, such as episodic and 
place memory (Bast, 2007; Bast, 2011), prefrontal and hippocampal disinhibition may impair 
attention and everyday memory tasks, respectively. Second, considering strong hippocampo-
prefrontal projections, hippocampal disinhibition may disrupt prefrontal-dependent cognitive 
function, such as attention, by disrupting prefrontal processing (Bast, 2011). 
To test these hypotheses, we began investigating the neuro-cognitive impact of prefrontal 
and hippocampal neural disinhibition in rats. We induced temporary prefrontal and 
hippocampal neural disinhibition, using acute microinfusion of subconvulsive doses of the 
selective GABA-A receptor antagonist picrotoxin into the medial prefrontal cortex (Pezze et 
al., 2014) or hippocampus (McGarrity et al., 2016) and examined the impact on translational 
behavioural tests of attention and everyday-type place learning. The hippocampal infusions 
targeted temporal (also referred to as ventral) to intermediate hippocampus, because this part 
of the hippocampus features strong hippocampo-prefrontal connectivity and corresponds to 
human anterior hippocampus, dysfunction of which has been implicated in schizophrenia 
(Bast, 2011). To link any cognitive effects to specific neural changes within prefrontal cortex 
or hippocampus, we measured how picrotoxin infusions affected neural activity in the 
vicinity of the infusion site, using in vivo electrophysiological recordings in anaesthetised 
rats. 
 
 
                                                          
2
 Note that tonic, i.e. long-lasting, neural disinhibition (such as resulting from reduced GABA neuron function in 
neuropsychiatric disorders or from intra-cerebral microinfusions of GABA-A antagonists in rat models) would 
be expected to interfere with both phasic inhibition, caused by transient increases in synaptic GABA following 
firing of GABA neurons, and with tonic inhibition, caused by ambient GABA (Farrant and Nusser, 2005). 
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Neural disinhibition in prefrontal cortex and hippocampus enhances burst firing of 
neurons within these regions 
In both the medial prefrontal cortex (Pezze et al., 2014) and the hippocampus (McGarrity et 
al., 2016), disinhibition by picrotoxin markedly enhanced firing of neurons in bursts, 
particularly increasing within-burst firing rate and prevalence of burst firing (e.g., as reflected 
by increased percentage of spikes in burst) within the prefrontal cortex and increasing 
prevalence of burst firing, accompanied by a moderate increase in overall firing rate, in the 
hippocampus (Fig. 2). Bursts are periods of relatively high firing that are separated by 
periods of comparatively little firing (Lisman, 1997). Our findings converge with the 
enhanced hippocampal burst firing reported following pharmaco- or optogenetic silencing of 
hippocampal inhibitory GABA interneurons in vitro (Lovett-Barron et al., 2012) and in 
awake mice (Royer et al., 2012) and suggest a key role of GABAergic inhibition in the 
regulation of prefrontal and hippocampal burst firing. 
Aberrant burst firing is likely to be detrimental for cognitive functions of both the 
disinhibited region and their projection sites. Bursts have been suggested to be key units of 
neural information processing, increasing the reliability and selectivity of neural 
communication, and burst firing is particularly effective in driving post-synaptic targets 
(Cooper, 2002; Izhikevich et al., 2003; Larkum, 2013; Lisman, 1997). In the visual cortex, 
short periods of vigorous firing in response to task-relevant stimuli, separated by relatively 
quiescent periods, have recently been associated with task-appropriate behavioural 
responding on a visual attention test, and it was proposed that such fine tuning of neural 
responses is widespread within cortical areas and important for a wide range of cognitive 
functions (Engel et al., 2016). Moreover, in the hippocampus, burst firing has been 
implicated in the encoding and readout of hippocampal memory (Takahashi and Magee, 
2009; Xu et al., 2012). Our electrophysiological findings, in conjunction with the behavioural 
findings we outline below, support that dysregulation of burst firing within the prefrontal 
cortex and hippocampus, by disruption of local GABA function, can disrupt both regional 
cognitive function, as well as the cognitive function of projection sites. 
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Neural disinhibition within the prefrontal cortex or hippocampus causes clinically 
relevant cognitive deficits 
 
Disruption of prefrontal-mediated cognitive function by prefrontal or hippocampal neural 
disinhibition 
To test for attentional deficits, we used the five-choice-serial-reaction-time (5CSRT) task. 
This task requires rats to sustain and divide attention across a row of five apertures to detect 
brief light flashes occurring randomly in one of the apertures and to respond to these flashes 
to receive food reward. The 5CSRT task resembles human continuous performance tests, and 
its validity for assessing prefrontal-mediated attentional mechanisms as impaired in 
schizophrenia and early age-related cognitive decline has been well established (Chudasama 
and Robbins, 2006; Lustig et al., 2013; Romberg et al., 2013). Acute prefrontal (Pezze et al., 
2014) or hippocampal (McGarrity et al., 2016) neural disinhibition by picrotoxin both caused 
attentional deficits on the 5CSRT test (Fig. 3A, B).  
Attention as measured on the 5CSRT test requires neural activity within the medial 
prefrontal cortex, with both neurotoxic lesions (Chudasama et al., 2012; Chudasama and 
Muir, 2001; Passetti et al., 2002; Pezze et al., 2009) and functional inhibition of this region 
by the GABA agonist muscimol (Pezze et al., 2014) markedly impairing attentional 
performance. Therefore, the attentional deficits caused by prefrontal picrotoxin, which are 
consistent with attentional impairments reported by others with medial prefrontal infusions of 
GABA-A antagonists in rats (Paine et al., 2011; Pehrson et al., 2013) and, recently, with 
optogenetic inactivation of parvalbumin-positive prefrontal GABA neurons in mice (Kim et 
al., 2016), suggest that sustained attention depends on appropriately tuned prefrontal neural 
activity, with both too little and too much causing attentional impairments (Pezze et al., 
2014). Similar to attention, aspects of cognitive flexibility, such as extra-dimensional 
response shifts, are disrupted by neurotoxic lesions of the medial prefrontal cortex (Birrell 
and Brown, 2000) or functional inactivation by the sodium channel blocker bupivacaine 
(Floresco et al., 2008), as well as by neural disinhibition of the medial prefrontal cortex 
(Enomoto et al., 2011; Gruber et al., 2010), also suggesting a requirement for appropriately 
tuned medial prefrontal neural activity. However, not all cognitive functions requiring the 
prefrontal cortex are disrupted by prefrontal neural disinhibition. Response inhibition, as 
measured by the ability to withhold premature responses on the 5CSRT task, is impaired by 
prefrontal functional inhibition (Murphy et al., 2012; Paine et al., 2011; Pezze et al., 2014) or 
lesions (Chudasama et al., 2012; Chudasama and Muir, 2001; Passetti et al., 2002; Pezze et 
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al., 2009), whereas prefrontal neural disinhibition does not change (Paine et al., 2011; Pezze 
et al., 2014) or, if more ventral portions of the medial prefrontal cortex are affected, may 
even improve response control (Murphy et al., 2012). This suggests that response inhibition 
requires prefrontal neural activity, but not the appropriate tuning of such activity. 
The selective attentional deficit on the 5CSRT test following hippocampal neural 
disinhibition (Fig. 3B), indicated by reduced accuracy without changes in any other 
performance measures, probably reflects disruption of extrahippocampal processing, most 
likely in prefrontal cortex or ventral striatum by way of strong hippocampal functional 
connectivity to these sites (Bast, 2011). Previous lesion studies suggest that the hippocampus 
itself plays, if at all, only a minor role in mediating sustained attention on the 5CSRT task 
and related tests (see discussion in McGarrity et al., 2016). In contrast, as discussed in the 
preceding paragraph, sustained attention requires balanced prefrontal neural activity. 
Sustained attention on the 5CSRT test also requires an optimal level of prefrontal (Granon et 
al., 2000) and ventral striatal (Pezze et al., 2007) dopamine receptor stimulation, which may 
be disrupted by hippocampal neural disinhibition, given that hippocampal stimulation 
activates the meso-prefrontal-ventral striatal dopamine system (Bast, 2007; Bast, 2011; 
Floresco et al., 2001; Lodge and Grace, 2011; Mitchell et al., 2000; Peleg-Raibstein et al., 
2005). The attentional deficits following hippocampal neural disinhibition highlight that 
regional neural disinhibition can affect cognitive functions beyond those normally depending 
on the disinhibited region and result in impairments of cognitive functions mediated by 
projection sites of the disinhibited region. 
The attentional deficits following hippocampal neural disinhibition, reflected by decreased 
response accuracy without changes in omissions on the 5CSRT test, are less pronounced than 
the attentional deficits following lesions (Chudasama et al., 2012; Chudasama and Muir, 
2001; Passetti et al., 2002; Pezze et al., 2009) or functional inhibition and disinhibition (Paine 
et al., 2011; Pezze et al., 2014) of the medial prefrontal cortex, which all manifest as 
decreases in accuracy alongside increases in omissions (additionally, lesions and functional 
inhibition reduce inhibitory response control, as reflected by increased premature responses). 
However, other experimental manipulations primarily targeting the afferent modulation of the 
prefrontal cortex cause selective reductions in accuracy without increasing omissions, 
including selective manipulations of the cholinergic (McGaughy et al., 2002) or 
dopaminergic (Granon et al., 2000) modulation of the prefrontal cortex. Selective reductions 
in accuracy, without increases in omissions, have also been reported in the triple transgenic 
mouse model of Alzheimer’s disease (Romberg et al., 2011) and the pilocarpine rat model of 
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temporal lobe epilepsy (Faure et al., 2014), where the primary pathology is not within the 
prefrontal cortex, but in medial temporal lobe regions, including the hippocampus. 
Interestingly, both the pilocarpine rat model (Kumar and Buckmaster, 2006) and the triple 
transgenic mouse model of Alzheimer’s disease (Davis et al., 2014) show hippocampal 
hyperexcitability. The finding that hippocampal neural disinhibition causes attentional 
impairments suggests that hippocampal hyperexcitability may contribute to the attentional 
deficits in these rodent models. 
 
Disruption of hippocampus-mediated memory function by hippocampal neural 
disinhibition 
To test for everyday-type memory deficits, we used the watermaze delayed-matching-to-
place (DMTP) task. This highly hippocampus-dependent test requires rats to learn within one 
trial the daily changing place of a hidden platform that offers escape from water (Bast et al., 
2009; Pezze and Bast, 2012; Steele and Morris, 1999), resembling the everyday task of 
remembering new places and routes. Similar place memory tests can be run in humans using 
virtual or real-space analogues of the watermaze, and such tests have revealed marked 
deficits in schizophrenia and age-related cognitive decline (Fajnerova et al., 2014; Hort et al., 
2007). Hippocampal neural disinhibition by picrotoxin markedly disrupted rapid place 
learning performance on the watermaze DMTP test, as reflected by a marked reduction of 
search preference for the new location, which rats had to learn within the first trial of the day 
(McGarrity et al., 2016) (Fig. 3C). Neural disinhibition within the medial prefrontal cortex 
did not impair such place learning performance, although it modulated behaviour on the 
DMTP task, biasing rats towards focused searching; experiments using functional inhibition 
of the medial prefrontal cortex by muscimol indicated that the prefrontal cortex is not 
required for this task (McGarrity et al., 2014). Previous studies suggest that performance on 
the watermaze DMTP test requires the hippocampus for the rapid encoding of new places and 
for the translation of such rapid place learning into behavioural performance. DMTP 
performance is disrupted by pharmacological manipulations targeting synaptic plasticity 
mechanisms mediated by NMDA (Steele and Morris, 1999) and dopamine receptors (Pezze 
and Bast, 2012) and by partial hippocampal lesions, including lesions restricted to temporal 
and intermediate hippocampus (Bast et al., 2009), which were targeted by the infusions in the 
study involving hippocampal neural disinhibition (McGarrity et al., 2016). Functional 
inhibition by the GABA agonist muscimol, targeting the intermediate hippocampus, also 
disrupts task performance (McGarrity et al., 2014). The requirement of temporal to 
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intermediate hippocampus probably reflects that these regions feature functional connectivity 
to frontal and subcortical sites necessary to translate hippocampal learning into performance, 
although the specific relevant brain sites remain to be determined (Bast, 2007; Bast, 2011; 
Bast et al., 2009; McGarrity et al., 2014). Overall, neural disinhibition, causing aberrant 
neuronal bursting, may disrupt everyday-type memory performance, as assessed on the 
watermaze DMTP task, by interfering with hippocampal encoding or readout of relevant 
place information or with passing on such information to hippocampal projection sites. 
The finding that hippocampal neural disinhibition disrupts hippocampus-dependent 
performance on the watermaze DMTP task (McGarrity et al., 2016) is consistent with other 
recent rodent studies reporting a learning-related increase of hippocampal inhibitory synapses 
(Ruediger et al., 2012) and impaired memory performance following disruption of 
hippocampal GABA neuron function by molecular-, opto- or pharmacogenetic approaches 
(Andrews-Zwilling et al., 2012; Caputi et al., 2012; Donato et al., 2013; Engin et al., 2015; 
Gilani et al., 2014; Lee et al., 2016; Lovett-Barron et al., 2014; Murray et al., 2011).  
Moreover, our findings support recent studies in humans and rodent models linking 
hippocampal overactivity and hyperexcitability to age-related memory deficits (Bakker et al., 
2012; Davis et al., 2014; Koh et al., 2010) and are consistent with the correlation of 
hippocampal overactivity with memory deficits in schizophrenia (Tregellas et al., 2014). 
However, hippocampal neural disinhibition may facilitate hippocampal synaptic plasticity 
(Martin et al., 2010; Wigstrom and Gustafsson, 1983). Such facilitation of hippocampal 
synaptic plasticity by neural disinhibition may under some circumstances be beneficial for 
memory, for example, if the neural disinhibition is spatio-temporally regulated by 
endogenous plasticity (Donato et al., 2013) or if there is a pre-existing deficit due to 
increased neural inhibition (Fernandez et al., 2007). Moreover, systemic injection of a 
selective inverse agonist to negatively modulate GABA-A receptors containing the alpha5 
subunit, which are predominantly expressed in hippocampus and constitute about 20% of 
hippocampal GABA-A receptors, has been reported to facilitate hippocampal plasticity and 
performance on the watermaze DMTP test (Dawson et al., 2006), although other studies 
reported that transgenic reduction of hippocampal alpha5 subunit-containing GABA-A 
receptor expression disrupts aspects of hippocampus-dependent memory (Engin et al., 2015; 
Prut et al., 2010). Interestingly, the selective inverse agonist at alpha5-subunit containing 
GABA receptors that was reported to enhance watermaze DMTP performance enhanced 
induction of long-term potentiation at hippocampal (Schaffer collateral) synapses in vitro, 
without affecting the number of stimulation-evoked population spikes, which may indicate 
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that stimulation-evoked neural burst firing was unchanged (Dawson et al., 2006). In contrast, 
hippocampal neural disinhibition caused by picrotoxin, which disrupted hippocampus-
dependent DMTP performance, altered the temporal organization of hippocampal neural 
activity, markedly enhancing burst-pattern firing (McGarrity et al., 2016). Overall, 
hippocampus-dependent memory performance appears to require hippocampal neural activity 
that is appropriately balanced by GABAergic inhibition, resembling the requirement of 
appropriately tuned prefrontal activity for prefrontal-dependent cognitive functions (Pezze et 
al., 2014). 
 
 
Significance of prefrontal and hippocampal inhibitory GABA transmission for distinct 
cognitive functions: distinct causal relationships linking regional neural activity to 
distinct cognitive functions  
The recent studies discussed above show that inhibitory GABA transmission within 
prefrontal cortex and hippocampus is required to regulate neuronal firing, especially burst-
pattern firing, and to sustain aspects of the cognitive functions supported by these regions and 
projection sites. Prefrontal neural disinhibition disrupts aspects of prefrontal-dependent 
attentional performance and of cognitive flexibility, similar to prefrontal lesions and 
functional inhibition/inactivation (Enomoto et al., 2011; Gruber et al., 2010; Pezze et al., 
2014), and hippocampal neural disinhibition disrupts hippocampus-dependent memory 
performance, similar to hippocampal lesions and functional inhibition
3
 (McGarrity et al., 
2016). This suggests that neural activity within the prefrontal cortex or hippocampus, 
respectively, relates to these cognitive functions via an inverted-U shaped function, with both 
too much and too little neural activity causing disruptions (Fig. 4A). Moreover, the finding 
that hippocampal neural disinhibition impairs attentional performance, which does not 
require hippocampal neural activity, but is mediated by prefrontal-striatal circuits, shows that 
the regulation of neural activity by GABAergic inhibition within a particular brain region can 
also be important for aspects of cognitive function that require balanced levels of neural 
activity within this region’s projection sites (McGarrity et al., 2016). In other words, attention 
                                                          
3
 It should be noted that permanent lesions and temporary functional inhibition or inactivation do not 
necessarily have the same cognitive and behavioural impact. Depending on the cognitive or behavioural 
function, lesions and temporary inhibition or inactivation may even have opposite effects, probably reflecting 
compensatory responses to permanent neural damage or lesion-induced changes going beyond the target 
region of the lesion (Wang et al., 2015). 
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is largely insensitive to reductions of hippocampal neuron activity, but is dirupted by aberrant 
tonic increases in hippocampal neural activity (Fig. 4B).  
However, other hippocampal and prefrontal functions may be less dependent on the 
regulation of regional neural firing by inhibitory GABA transmission. In contrast to 
prefrontal and hippocampal lesions or functional inhibition, neither medial prefrontal nor 
hippocampal neural disinhibition disrupt inhibitory response control on the 5CSRT test (as 
reflected by premature or perseverative responses; McGarrity et al., 2016; Pezze et al., 2014). 
This suggests that such response control requires neural activity within the hippocampo-
prefrontal circuit, but not the appropriate tuning of such activity. In other words, response 
control can be sustained as long as neural activity within the hippocampo-prefrontal circuit is 
above a minimal level (Fig. 4C). 
Finally, there are also behavioural processes that are supported by prefrontal or 
hippocampal neural activity that may be enhanced by tonic reductions of local GABA 
transmission. Neural disinhibition of the (temporal) hippocampus (similar to direct chemical 
or electrical stimulation; Bast and Feldon, 2003) enhances locomotor activity (Bast et al., 
2001a; McGarrity et al., 2016), which depends on neural activity within the temporal 
hippocampus and is reduced by temporary functional inhibition or inactivation of this region 
by muscimol or the sodium channel blocker tetrodotoxin (Bast et al., 2001b). Similarly, 
prefrontal neural disinhibition increases, whereas prefrontal functional inhibition decreases 
locomotor activity (Pezze et al., 2014). These findings suggest that hippocampal and 
prefrontal neural activity drives locomotor activity, with a monotonic positive relation 
between regional neural activity and locomotion (Fig. 4D). These locomotor effects may 
reflect a positive modulation of ventral striatal dopamine transmission by neural activity 
within the hippocampo-prefrontal circuit (Bast and Feldon, 2003; Floresco et al., 2001; 
Karreman and Moghaddam, 1996; Lodge and Grace, 2011; Mitchell et al., 2000). 
In summary, regulation of prefrontal and hippocampal neural activty by GABAergic 
inhibition is important for cognitive and behavioral functions supported by these regions and 
by distal brain sites functionally connected to these regions. Neural disinhibition in prefrontal 
cortex and hippocampus may have distinct effects on distinct cognitive or behavioural 
functions supported by these regions, reflecting distinct relationships of inhbitory GABA tone 
and neural activity to distinct functions: some functions require an intact inhibitory GABA 
tone and appropriately balanced neural activity levels, wheras other functions do not require 
the tuning of neural acitivy by GABAergic inhibition (as long as neural activity remains 
subconvulsive). 
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Prefrontal and hippocampal GABA dysfunction in neuropsychiatric disorders may 
account for important cognitive deficits characterizing these disorders 
Prefrontal and hippocampal GABA dysfunction has been implicated in schizophrenia and 
age-related cognitive decline, including early Alzheimer’s disease (Benes and Berretta, 2001; 
Busche and Konnerth, 2016; Heckers and Konradi, 2015; Huang and Mucke, 2012; Nava-
Mesa et al., 2014; Ruzicka et al., 2015; Stanley et al., 2012). The neuro-cognitive effects of 
acute pharmacological prefrontal and hippocampal neural disinhbition discussed above are 
mainly relevant to early stages of these disorders,  before chronic disinhibition-induced 
neural hyperactivity may lead to compensatory or excitotoxic effects, resulting in regional 
brain hypofunction and atrophy characteristic of later disease stages (Heckers and Konradi, 
2015; Huang and Mucke, 2012; Krystal and Anticevic, 2015; Schobel et al., 2013). Given the 
close link between neural activity and metabolic activation (Sokoloff, 1981), the enhanced 
hippocampal neural activity, especially of burst-pattern firing, caused by acute hippocampal 
GABA antagonism (McGarrity et al., 2016) is consistent with the hippocampal metabolic 
overactivity at rest reported by functional imaging studies in early stages of both 
schizophrenia and age-related cognitive decline (Bakker et al., 2012; Schobel et al., 2013; 
Schobel et al., 2009; Sperling et al., 2010). 
The rodent 5CSRT and watermaze DMTP tests have high validity to measure deficits in 
attention and memory relevant to clinical disorders, with related human paradigms – 
continuous performance tests and place learning tests in virtual and real-space analogues of 
the watermaze, respectively – revealing marked deficits in schizophrenia and age-related 
cognitive decline (Chudasama and Robbins, 2006; Fajnerova et al., 2014; Hort et al., 2007; 
Lustig et al., 2013; Romberg et al., 2013). Therefore, the findings that prefrontal and 
hippocampal neural  disinhbition in rats causes impairments on these tests supports that 
prefrontal and hippocampal GABA dysfunction contributes to clinically relevant attentional 
and memory deficits. The memory and attentional deficits caused by hippocampal neural 
disinhibition (McGarrity et al., 2016) also support that causal relationships underly the 
recently reported correlations of hippocampal overactivity with both memory and attentional 
deficits in schizophrenia patients (Tregellas et al., 2014) and the association of hippocampal 
overactivity with memory deficits in amnestic mild cognitive impairment (Bakker et al., 
2012). 
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Implications for pharmacological strategies to treat cognitive deficits  
Drugs targeting neural network disruptions resulting from prefrontal and hippocampal neural 
disinhibition may offer much-needed new treatment opportunities for cognitive deficits. As 
discussed above, recent findings show that key cognitive functions, including attention and 
memory, depend on balanced neural activity within prefrontal cortex or hippocampus, with 
both too little and too much activity being detrimental. This has important implications for 
drug treatments targeting the adverse neuro-cognitive effects of GABA dysfunction: Drugs 
simply suppressing neural activity will be of limited suitability to treat cognitive deficits. 
Instead, it is critical to rebalance aberrant neural activity – that is, to curb excessive excitation 
and burst firing, without suppressing normal firing, as required for cognitive function. 
Several candidate drugs are available that may achieve such rebalancing of aberrant neural 
activity induced by neural disinhibition. Of particular interest are second generation 
antiepileptics, including levetiracetam and lamotrigine, and positive allosteric modulators 
(PAMs) acting at the metabotropic glutamate receptor 2 (mGluR2). The second-generation 
antiepileptics lamotrigine and levetiracetam block excessive hippocampal burst firing in 
vitro, while leaving basal neural activity largely unaffected, an effect suggested to reflect 
effects on state-dependent cation currents that mainly contribute to high-frequency firing (De 
Smedt et al., 2007; Kuo and Lu, 1997). Levetiracetam has been shown to ameliorate aberrant 
cortico-hippocampal neural activity and improve cognitive deficits in rodent models of age-
related cognitive decline (Haberman et al., 2017; Koh et al., 2010; Robitsek et al., 2015; 
Sanchez et al., 2012) and in human cognitive aging (Bakker et al., 2012). Lamotrigine has 
been under consideration for repurposing to ameliorate schizophrenia-related cognitive 
deficits associated with cortico-hippocampal neural disinhibition, and has shown some 
promise in pre-clinical schizophrenia models, with limited benefits in clinical trials (Large et 
al., 2011). The failure in clinical trials may reflect that the proposed rebalancing mechanism 
of lamotrigine would mainly benefit early-stage schizophrenia patients, characterised by 
aberrant regional brain hyperactivity, but be of limited benefit in long-standing patients, as 
typically included in clinical trials, who show regional brain hypoactivity (Anticevic et al., 
2015; Krystal and Anticevic, 2015). PAMs at the mGluR2 may rebalance activity by 
selectively curbing excessive glutamate release through activity-dependent stimulation of 
mGluR2, a presynaptic autoreceptor controlling glutamate release at forebrain terminals (Fell 
et al., 2012). The mGluR2 has received much interest as a schizophrenia drug target, fuelled 
by findings that an orthosteric agonist improved cognitive deficits and psychosis-related 
changes in rat models of schizophrenia, as well as positive and negative symptoms in an 
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initial phase 2 clinical trial, although subsequent larger and longer clinical trials failed to 
support effectiveness against schizophrenia symptoms (Curley, 2012) and, more recently, an 
mGluR2 PAM also failed a phase 2 clinical trial (Litman et al., 2016). Importantly, as 
considered above with respect to lamotrigine, the proposed rebalancing mechanism of 
mGluR2 stimulation would mainly benefit early-stage schizophrenia patients, characterised 
by aberrant regional brain hyperactivity, but be of limited benefit in long-standing patients, as 
typically included in clinical trials, who show regional brain hypoactivity (Anticevic et al., 
2015; Krystal and Anticevic, 2015). Consistent with this possibility, a recent re-analysis of 
the clinical trials with the mGluR2 orthosteric agonist indicated beneficial effects in early-
stage, but not chronic, schizophrenia patients (Krystal and Anticevic, 2015). 
What about drugs directly targeting GABA receptor function? Interestingly, substantial 
drug discovery efforts to improve cognitive function by targeting GABA receptors have 
focused on a negative modulation of GABA receptors, such as by inverse agonists selective 
for alpha 5-containing GABA receptors (Ballard et al., 2009; Dawson et al., 2006). However, 
the more recent findings reviewed here, highlighting the requirement of appropriate GABA 
tone in prefrontal cortex and hippocampus for important cognitive functions, including 
attention and memory, as well as the emergence of neural disinhibition as a feature of many 
disorders characterized by cognitive deficits, suggest a different approach. Drugs positively 
modulating GABA receptor function may have potential for ameliorating the neuro-cognitive 
effects in disorders associated with neural disinhibition, as long as overstimulation of 
inhibitory GABA receptor function can be avoided, as this would interfere with cognitive 
function. GABA receptor modulators selective for receptor subunits with preferentially 
prefrontal and hippocampal expression, such as alpha 2 and 5, have received particular 
interest as they may minimise sedation (Rudolph and Knoflach, 2011; Vinkers et al., 2010). 
Recent studies in rats showed that a PAM selective for alpha 5-containing GABA receptors 
reduces hippocampal hyperexcitability in the methylazoxymethanol acetate (MAM) 
developmental model of schizophrenia (although the drug also reduced baseline hippocampal 
excitability in control rats, which may interfere with some hippocampus-dependent functions) 
(Gill and Grace, 2011) and ameliorates age-related memory impairments linked to 
hippocampal GABA dysfunction and hyperexcitability (Koh et al., 2013). However, an alpha 
2-selective partial agonist failed to improve cognition in schizophrenia patients, with 
potential reasons discussed by the authors including insufficient receptor activity and sedative 
side effects due to insufficient subunit selectivity (Buchanan et al., 2011). As discussed above 
for the other drug candidates, long-standing, chronic patients, as typically included in clinical 
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trials, who show regional brain hypoactivity may show little benefit from any treatment 
targeting aberrant neural activity (Anticevic et al., 2015; Krystal and Anticevic, 2015). 
Moreover, the effectiveness of GABAergic approaches in treating prefrontal and 
hippocampal disinhibition in schizophrenia may be limited because the GABA system may 
be compromised beyond repair - indeed, GABA-A receptors are already upregulated in 
schizophrenia patients, presumably as a compensatory response to presynaptic dysfunction 
(Benes and Berretta, 2001; Guidotti et al., 2005; Heckers and Konradi, 2015; Lewis and 
Moghaddam, 2006). 
 
 
Conclusions and future directions 
Prefrontal and hippocampal neural disinhibition causes aberrant regional neuron firing, 
characterized by enhanced bursting, and disrupts some clinically relevant cognitive functions 
of these regions, including attention and memory, whereas some cognitive and behavioural 
functions supported by these regions (e.g., inhibitory response) are spared. This highlights 
that distinct cognitive and behavioural functions supported by a brain region can show 
distinct dependencies on regional inhibitory GABA transmission, reflecting distinct 
relationships to regional neural activity: some functions require an appropriate inhibitory 
GABA tone and balanced levels of neural activity, whereas other functions may not (as long 
as the disinhibition remains subconvulsive). To characterize the distinct causal relationships 
of prefrontal and hippocampal GABA tone and neural activity to specific cognitive functions, 
future studies will have to compare systematically the impact of both functional inhibition 
and functional disinhibition on tests of such cognitive functions. Acknowledging the diversity 
of the various receptor and neuron types making up the inhibitory GABA system (Ascoli et 
al., 2008; Rudolph and Knoflach, 2011), studies using intra-cerebral microinfusions of 
broadly acting GABA agonists and antagonists may be complemented by studies using more 
selective ligands, to target specific GABA receptors subtypes (Rudolph and Knoflach, 2011), 
and opto- and pharmacogenetic methods, to modulate GABA transmission presynaptically 
with some specificity for different interneuron types (Lovett-Barron et al., 2014; Nguyen et 
al., 2014; Royer et al., 2012). 
Consistent with the idea that regional neural disinhibition can disrupt cognitive processing 
in distal sites, hippocampal neural disinhibition disrupts attentional performance that does not 
require the hippocampus, but is mediated by prefrontal-striatal mechanisms (McGarrity et al., 
2016). This supports that hippocampal dysfunction can partly manifest through deficits in 
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prefrontal function, consistent with strong hippocampo-prefrontal functional connectivity 
(Bast, 2011; Meyer-Lindenberg et al., 2005). Future studies combining regional neural 
disinhibition with additional behavioural tests will be required to characterize further the 
‘distal cognitive impact’, i.e. the significance for cognitive functions mediated by efferent 
sites, of regional GABA tone and neural disinhibition (e.g., does hippocampal neural 
disinhibition also disrupt other prefrontal cognitive processes, such as aspects of cognitive 
flexibility?). Moreover, neurophysiological measurements in projection sites will be required 
to characterize the brain-wide effects of regional neural disinhibition. Using translational 
imaging methods (e.g., metabolic radiological imaging or EEG measurements) for such 
measurements would make it possible to examine the role of hippocampo-prefrontal neural 
disinhibition in generating important clinical biomarkers (e.g., regional metabolic 
hyperactivity and aberrant EEG oscillations) of some of the disorders associated with neural 
disinhibition (see section on ‘Prefrontal and hippocampal neural disinhibition in 
neuropsychiatric disorders characterized by cognitive deficits’). 
The reviewed findings suggest that prefrontal and hippocampal neural disinhibition 
contributes to important cognitive deficits, including attentional and memory deficits, in 
neuropsychiatric disorders characterized by such neural disinhibition, including 
schizophrenia and age-related cognitive decline (Table 1). Therefore, aberrant neural activity 
caused by neural disinhibition is a promising target for treatments aimed at restoring 
important cognitive functions in these disorders, especially at early disease stages, when 
disinhibition-induced prefrontal and hippocampal hyperactivity is prevalent, rather than 
hypoactivity and atrophy that characterize later disease stages (Anticevic et al., 2015; Huang 
and Mucke, 2012; Krystal and Anticevic, 2015). Suitable pharmacological treatments will 
have to rebalance the disinhibition-induced aberrant neural activity by curbing excessive 
excitation and burst firing, while leaving intact normal firing, as required for cognitive 
function. Candidate drugs include second generation antiepileptics, including lamotrigine and 
levetiracetam, and mGluR2 PAMs. Pre-clinical studies in rodent models of prefrontal and 
hippocampal neural disinhibition can provide proof-of-concept for the suggested rebalancing 
actions of these candidate drugs, using a two-step approach, involving i) electrophysiological 
studies to determine if a candidate drug rebalances aberrant neural activity and ii) 
translational behavioural assays to determine if the drug ameliorates impairments of clinically 
relevant cognitive functions. Such studies could pave the way for clinical trials, where the 
challenge will be to include patients at early disease stages who are most likely to benefit 
from treatments rebalancing aberrant neural activity. 
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Nomenclature of Targets and Ligands 
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 
Guide to PHARMACOLOGY (Southan et al., 2016), and are permanently archived in the 
Concise Guide to PHARMACOLOGY 2015/16 (Alexander et al., 2015). 
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Table 1 
Some important neuropsychiatric disorders that have been associated with cortico-hippocampal 
GABA dysfunction. All of these disorders show cognitive impairments (Millan et al., 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Disorder References supporting GABA dysfunction 
Schizophrenia Benes and Berretta, 2001; Fung et al., 2010; 
Guidotti et al., 2005; Heckers and Konradi, 
2015; Lewis and Moghaddam, 2006; Lisman et 
al., 2008; O'Donnell, 2011; Ruzicka et al., 2015 
Cognitive ageing and Alzheimer’s Busche and Konnerth, 2016; Huang and 
Mucke, 2012; Nava-Mesa et al., 2014; Spiegel 
et al., 2013; Stanley et al., 2012;  Thomé et al., 
2016 
Autism Han et al., 2014; Rubenstein and Merzenich, 
2003 
Depression Luscher et al., 2011; Rajkowska et al., 2007 
Bipolar disorder Konradi et al., 2011 
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Fig. 1 Regional GABA dysfunction may disrupt regional function and the function of 
projection sites. Deficient function of inhibitory GABA interneurons within the prefrontal 
cortex or hippocampus disrupts the spatio-temporal control of excitatory glutamatergic 
neurons within these regions, causing aberrant firing of these neurons (1), which may disrupt 
the cognitive functions normally mediated by these regions (2). In addition, such aberrant 
firing may cause aberrant drive of neurons in projection sites, which may disrupt the 
functions normally mediated by these projection sites (3).  
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Fig. 2 Neural disinhibition in prefrontal cortex and hippocampus enhances burst firing of 
neurons within these regions. Following local microinfusions of the GABA antagonist 
picrotoxin into the medial prefrontal cortex (A) or hippocampus (B) of anaesthetised rats, the 
most marked effect revealed by in vivo electrophysiological recordings of multi-unit activity 
in the vicinity of the infusion sites is enhanced neuronal burst firing. A In the medial 
prefrontal cortex, regional neural disinhibition by picrotoxin primarily increases within-burst 
firing rate and, at the higher picrotoxin dose, also increases the prevalence of bursts, as 
reflected by an increased percentage of spikes fired in bursts.  B In the hippocampus, local 
  
This article is protected by copyright. All rights reserved. 
picrotoxin infusion markedly increases the prevalence of bursts, as reflected, for example, by 
an increased percentage of spikes fired in bursts, accompanied by a comparatively moderate 
increase in overall firing rate. All values show multi-unit recording data normalized to 
baseline (average across the six 5-min blocks before infusion) and show mean+SEM; 
prefrontal data graphs are adapted from Pezze et al. (2014) and hippocampal data from 
McGarrity et al. (2016). 
  
  
This article is protected by copyright. All rights reserved. 
 
Fig. 3 Neural disinhibition within medial prefrontal cortex and hippocampus causes 
clinically relevant attentional and memory deficits. A, B Attentional deficits: Neural 
disinhibition in the medial prefrontal cortex or hippocampus disrupts attentional performance 
on the five-choice-serial-reaction-time (5CSRT) task. The 5CSRT task requires rats to sustain 
and divide attention across a row of five apertures to detect brief light flashes occurring 
randomly in one of the apertures and to respond to these flashes to receive food reward. 
Following local microinfusions of the GABA antagonist picrotoxin into the medial prefrontal 
cortex (A) or hippocampus (B), rats show reduced attentional performance, as reflected by a 
reduced percentage of correct responses and, in case of the prefrontal disinhibition,  also an 
increase in omitted trials. C Memory deficits: Neural disinhibition in the hippocampus 
disrupts rapid place learning performance on the watermaze delayed-matching-to-place 
(DMTP) test. This highly hippocampus-dependent test requires rats to learn within one trial 
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the daily changing place of a hidden platform that offers escape from water, resembling the 
everyday task of remembering new places and routes. Following hippocampal picrotoxin 
microinfusion, rats show reduced one-trial place learning performance, as reflected by a 
marked reduction in search preference for the correct location. Prefrontal data graphs are 
adapted from Pezze et al. (2014) and hippocampal data graphs from McGarrity et al. (2016). 
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Fig. 4 Distinct causal relationships link neural activity within medial prefrontal cortex and 
hippocampus to distinct cognitive and behavioural processes. Studies examining the 
cognitive and behavioural impact of bidirectional changes of neural activity within the medial 
prefrontal cortex or hippocampus, including by local infusions of GABA agonists and 
antagonists, show that neural activity within these regions can be linked to distinct cognitive 
and behavioural processes by distinct causal relationships. A Inverted U-shaped relationship, 
with cognitive or behavioural process requiring a balanced level of neural activity and both 
too little and too much neural activity causing impairments; example: relationship between 
prefrontal neural activity and attentional performance and between hippocampal neural 
activity and rapid place learning performance. B Cognitive or behavioural process is not 
affected by reductions in neural activity, but impaired by increases in neural activity; 
example: relationship between hippocampal neural activity and attentional performance. C 
Cognitive or behavioural process can be sustained as long as neural activity is above a 
minimal level; example: relationship between hippocampal and prefrontal neural activity and 
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response control. D Monotonic positive relationship between neural activity and cognitive or 
behavioural process, with decreases in neural activity reducing the process and increases in 
neural activity increasing the process; example: relationship between hippocampal and 
prefrontal neural activity and locomotor activity. 
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